


Date of Preparation: 2/18/2015



Signature

DONALD P. LEVINE, M.D.

OFFICE ADDRESS:

University Health Center-5C
4201 St. Antoine
Detroit, MI 48201
Telephone: (313) 577-0348
E-mail: Dlevine@intmed.wayne.edu

PERSONAL DATA:

EDUCATION:

1967 B.A. Degree, University of Michigan, Ann Arbor, MI
1967-68 University of Illinois School of Law, Champagne Urbana, IL
1972 M.D. Degree, Wayne State University School of Medicine,
Detroit, MI

POSTGRADUATE TRAINING:

1972-73 Intern, Wayne State University, Hutzel Hospital Medical Unit, Department of
Medicine, Division of Infectious Diseases, Wayne State University School of
Medicine, Detroit, MI
1973-75 Resident, Internal Medicine, Wayne State University, Hutzel Hospital Medical
Unit, Detroit, MI
1975-76 Trainee, Infectious Diseases and Fellow in Medicine, Department of Medicine,
Division of Infectious Diseases, Wayne State University, Detroit, MI
1976-78 Trainee, Infectious Diseases and Chief Fellow in Medicine, Department of
Medicine, Division of Infectious Diseases, Wayne State University School of
Medicine, Detroit, MI
1977-78 NIH Research Fellow (recipient of an award from the National Institute of
Neurological and Communicative Disorders and Stroke).

Donald P. Levine, M.D.

Curriculum Vitae

Page 2 of 33

FACULTY APPOINTMENTS:

1978-86	Assistant Professor of Medicine, Department of Medicine, Wayne State University School of Medicine, Detroit, MI
1984-85	Acting Chief, Division of Infectious Diseases, Wayne State University School of Medicine, Detroit, MI
1985-Present	Adjunct Assistant Professor, College of Pharmacy and Allied Health Professions and the Department of Pharmacy Practice, Wayne State University, Detroit, MI
1986-94	Associate Professor of Medicine, Department of Medicine, Wayne State University School of Medicine, Detroit, MI
1994-Present	Professor of Medicine, Department of Medicine, Wayne State University School of Medicine, Detroit, MI
2000-2012	Division Chief, Division of General Internal Medicine, Wayne State University School of Medicine, Detroit, MI
2004-2008	Interim Chief, Division of Rheumatology, Wayne State School of Medicine, Detroit, MI
2010-Present	Adjunct Professor, College of Pharmacy and Allied Health Professions and the Department of Pharmacy Practice, Wayne State University, Detroit, MI
2012-Present	Associate Vice Chair for Continuing Medical Education and Community Affairs, Department of Medicine, Wayne State University

HOSPITAL APPOINTMENTS:

1981-2001	Chief, Division of Infectious Diseases, Detroit Receiving Hospital, Detroit, MI
1992-Present	Vice-Chief, Department of Medicine, Detroit Receiving Hospital, Detroit, MI
1998-2000	Vice-Chief of Staff, Detroit Receiving Hospital, Detroit, MI
2000-2002	Chief of Staff, Detroit Receiving Hospital, Detroit, MI
2006-2008	Chief of Staff, Detroit Receiving Hospital, Detroit, MI
2008-2012	Past Chief of Staff, Detroit Receiving Hospital, Detroit, MI

DEPARTMENT AND HOSPITAL COMMITTEES:

1978-Present	Chairman, Pharmacy and Therapeutics Committee (now called the Medication Use Committee), Detroit Receiving Hospital, Detroit, MI
1978-2000	Chairman, Infection Control Committee, Detroit Receiving Hospital, Detroit, MI
1992	Risk Management Committee of the Department of Internal Medicine, Wayne

State University, Detroit, MI

1992-97 Member, Medical Executive Committee, Detroit Receiving Hospital, Detroit, MI

1994-97 Member, Joint Conference Committee, Detroit Receiving Hospital, Detroit, MI

2000-2002 Chairman, Medical Staff Operations Committee, Detroit Receiving Hospital, Detroit, MI

WAYNE STATE UNIVERSITY COMMITTEES

2012-Present Member, Executive Committee

DETROIT MEDICAL CENTER COMMITTEES:

1998-2000 Chairman, Detroit Medical Center System Wide Pharmacy and Therapeutics Committee

1998-Present Member, DMC System Wide Pharmacy and Therapeutics Committee

1998-Present Member, DMC System Wide Antimicrobial Subcommittee

1998-2012 Member, DMC Medical Executive Committee

1998-Present Chairman, Medication Use Committee, Detroit Receiving Hospital

2000-2012 Member, DMC Executive Management Team

PROFESSIONAL SOCIETIES:

Member	American Society for Microbiology
Fellow	American College of Physicians
Fellow	Infectious Diseases Society of America
Member	Society of General Internal Medicine
Member	Association of Chiefs of General Internal Medicine
Member	International Society for Cardiovascular Infectious Diseases

MEDICAL LICENSURE:

1976 Licensure - State of Michigan

BOARD CERTIFICATION

1976 Diplomate, American Board of Internal Medicine

1982 Diplomate, Infectious Diseases, American Board of Internal Medicine

HONORS AND AWARDS:

Donald P. Levine, M.D.
Curriculum Vitae
Page 4 of 33
1997, 02

College Teaching Award, Wayne State University

1997-99, 01, 03, 05-06 **Best Doctors In America**
2007-2008, 2009-2010, **2011, 2012, 2013, 2014**

2006 Distinguished Teacher Award, Wayne State University

2006 Gold Humanism Honor Society

2007 Alpha Omega Alpha

2008 School of Medicine Teaching Award

2009 Emanuel Wolinsky Award awarded by Infectious Disease Society of America for best clinical paper published in 2009.

SERVICE

Wayne State University

2000-2001 Chairman, Internal Review Committee, Department of Emergency Medicine, Wayne State University

2004 Chairman, Family Medicine Internal Review Committee, Detroit Receiving Hospital, Detroit, MI

2005-Present Chairman, Emergency Medicine Chair Search Committee, Wayne State University School of Medicine

2008-2009 Member, Internal Review Committee, Department of Pediatrics, Wayne State University.

2008-2009 Member, Internal Review Committee, Department of Physical Medicine and Rehabilitation, Wayne State University.

2012-Present

Scholarly Service

2007-Present Consensus Guideline Panel: Infectious Diseases Society of America, "Management of Methicillin-Resistant *Staphylococcus aureus* Infections"

2007-Present Consensus Guideline Panel: Infectious Diseases Society of America, American Society of Hospital Pharmacists, Infectious Disease Pharmacist Society, "Therapeutic Monitoring of Vancomycin in Adult Patients".

2008-Present Section Editor: Current Infectious Disease Reports

2011-Present Editorial Board member: The Scientific World Journal

2012 Faculty Supervisor, World Student Health Organization Clinic, Port Lopez, Ecuador, March 3-March 13, 2012.

2012-Present Member: Data Safety Monitoring Board: Novartis ACZ885: Canakinum

2013-2014 **Member, Internal Review Committee, Department of Medicine, Wayne State University**

2014 **Faculty Supervisor, World Student Health Organization Clinic, Haiti, March 14-March 20, 2014.**

Review of Manuscripts

1. Archives of Internal Medicine
2. Reviews of Infectious Diseases
3. Annals of Internal Medicine
- 4. Clinical Infectious Disease**
5. Drug
6. Annals of Emergency Medicine
7. Journal of Musculoskeletal Diseases
- 8. European Journal of Clinical Microbiology**
9. Infection and Immunity
10. Journal of Infectious Diseases
- 11. European Journal of Clinical Microbiology and Infectious Diseases**
12. Clinical Microbiology and Infectious Diseases
13. Clinical and Diagnostic Laboratory Immunology
- 14. Pharmacotherapy**
15. American Heart Journal
16. Journal of Medical Microbiology
17. Infections in Medicine
- 18. Journal of Clinical Microbiology**
19. American Journal of the Medical Sciences
- 20. Antimicrobial Agents and Chemotherapy**
- 21. Journal of Tropical Medicine**

Donald P. Levine, M.D.

Curriculum Vitae

Page 6 of 33

22. Circulation

23. BMC Infectious Diseases

24. BMC Nephrology

25. Scientific World Journal

26. International Journal of Infectious Disease

27. Infectious Disease and Therapy

28. Clinical Therapeutics

29. Journal of the International Society of Providers of AIDS Care

30. JAMA

TEACHING:

1978-Present Faculty at Wayne State University

1996 –Present Year II Medical Student lecture: Infective Endocarditis

Year II Medical Student lecture: Pneumonia

Year II Microbiology Case studies

1978-Present Attending teaching rounds Infectious Diseases and General Internal Medicine

Mentorship

Wayne State University Students 2013-2014:

Allsion Zarbo

David Broome

Scott Dawsey

Jonathan Gwizdala

Christopher Jackson

Paul Kudla

Sachin Mehta

Darshan Patel

Priyanka Singh

Lisa Tsang

Course Development

1996 – 1998 Course Curriculum Development, Microbiology and Infectious Diseases, Year II Medical Students, Wayne State University

GRANT SUPPORT:

- 2013-** **A Multicenter, 2-Cohort Study to Describe the Safety and Efficacy of Ceftaroline Fosamil in Subjects with *Staphylococcus aureus* Bacteremia or With Persistent Methicillin-Resistant *Staphylococcus aureus* Bacteremia, Cerexa \$19,885 per patient**
- 2012-** **A Phase III, Randomized, Multicenter, Double-Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime-Avibactam (CAZ-AVI, formerly CAZ104) versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis, With a Gram-Negative Pathogen in Hospitalized Adults. AstraZeneca \$36,802.54 per patient**
- 2011-2013** **NIHAI2008025 BAA-NIAID-Sub award Duke University Medical Center, PI Donald Levine. 2010-2015. A Phase 2 Multi Center, Randomized, Open Label Comparative Study to Assess the Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Patients with Intravenous Catheter-Associated Bloodstream Infections (BSI) due to Staphylococci. \$846,473**
- 2008 Paratek Pharmaceuticals. A randomized, evaluator blinded, phase 3 study to compare the safety and efficacy of PTK 0796 with linezolid in the treatment of skin and skin structure infection. \$138,499.
- 2008 Cubist Pharmaceuticals. A Phase 2 multi-center, randomized, double-blind study to describe the safety, efficacy and pharmacokinetics of daptomycin 10 mg/kg/day and vancomycin for the treatment of methicillin-resistant *Staphylococcus aureus* bacteremia (DAP HDSA 07 05). Investigator initiated study. \$139,351.
- 2008-2011. Cubist Pharmaceuticals 4-20910. A Phase 4 Multicenter, randomized, double-blind study to describe the efficacy and safety of cubicin with and without initial gentamicin combination therapy in the treatment of *S. aureus* infective endocarditis. \$128,000.
- 2007 Cerexa, Inc. #P903-06. A Phase 3, Multi-Center, Randomized, Double-Blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline versus Vancomycin plus Aztreonam in Adult Subjects with Complicated Skin and Skin Structure Infections.
- 2005 – 2006 Theravance, Protocol #0018 Phase 3 randomized, double-blind, multinational trial of intravenous telavancin vs. vancomycin for treatment of complicated gram-positive skin & skin structure infection w/ a focus on patients w/infections due to methicillin – resistant staphylococcus aureus. \$17,322.00 per case.
- 2004 – 2007 Theravance, Protocol #0018 Phase 3 randomized, double-blind, multinational trial of intravenous telavancin vs. vancomycin for treatment of complicated gram-positive skin & skin structure infection w/ a focus on patients w/infections due to methicillin – resistant staphylococcus aureus. \$17,322.00 per case.
- 2004-2007 Wyeth Research #3074A1-308-WW A Phase 3, Multicenter, Randomized,

- Double-Blind, Comparative Study of the Efficacy and Safety of Tigecycline vs. Levofloxacin to Treat Subjects Hospitalized with Community-Acquired Pneumonia. \$43,396.20.
- 2004 – 2005 PPD/Cubist #DAP-4PSW-03-03Cubicin TM for Post-Surgical Wound Infections. \$4,500.00.
- 2002 – 2004 Cubist #DAP-IE-01-02 A Phase 3, Multicenter, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of Daptomycin Compared to Conventional Therapy in the Treatment of Subjects with Infective Endocarditis or Bacteremia Due to Staph. \$91,500.
- 2002 – 2005 Nabi Protocol 1407 Initial Safety and Pharmacokinetics Trail of Immune globulin to Staphylococcus aureus Capsule Polysaccharide (Altastaph) in Subjects with Persistent S. aureus Bacteremia. \$1,500.00.
- 2000 – 2005 AstraZeneca Pharmaceutical LP 3591IL/0079 A Multicenter, Randomized, Double-Blind, Comparative Trials of IV Merren (Menopenen, ICI 194,660)vs Primaxin IV (Imipenen-Cilastatin in the Treatment of Hospitalized Subjects with Complicated Skin and Skin Structure Infections. \$223,970.00
- 2000 – Present Bristol-Myers Squibb. A Randomized, Double-Blind, Multi-Center, Comparative Phase III Study of Intravenous BMS-284756 with or without Oral BMS-284756 Follow-up Versus Intravenous Piperacillin/Tazobactam with or without Oral Amoxicillin/Clavulanate Follow-up in the Treatment of Complicated Skin and Skin Structure Infections. \$46,800.
- 2000 – Present Ortho-McNeil Pharmaceuticals. Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin 750 mg Once Daily for Five Days versus Levofloxacin 500 mg Once Daily for 10 Days in the Treatment of Mild to Severe Community Acquired Pneumonia in Adults (CAPSS-150). \$25,000.
- 2000 – Present Ortho-McNeil Pharmaceuticals. Multicenter, Open-Label, Non-Comparative Study to Evaluate the Safety and Efficacy of Levofloxacin 750 mg Once Daily for Five Days in the Treatment of Mild to Severe Community Acquired Pneumonia in Adults (CAPSS-171). \$25,000.
- 1999 – Present Cubist Pharmaceuticals. A Multicenter, Open-Label, Non-Comparative Study to Assess the Safety and Efficacy of IV Cidecin™ (Daptomycin) in the Treatment of Subjects with Infections due to Gram-Positive Bacteria that are Resistant to Vancomycin or Who Are Otherwise Refractory to, or Contraindicated for Currently Available Therapy. \$20,000.
- 1999 – Present Cubist Pharmaceuticals. A Multicenter, Open-Label, Randomized Study to Compare the Safety and Efficacy of IV Cidecin™ (Daptomycin) with that of Vancomycin in the Treatment of Bacterial Infections due to Gram-Positive Bacteria. \$25,000.

Donald P. Levine, M.D.

Curriculum Vitae

Page 9 of 33

1999 – 01

Rhone-Poulenc Rorer. Non-Comparative, Open-Labeled, Phase III, Multicenter Study of Synercid® 7.5 mg/kg I.V. Q 8 Hours In The Treatment of 20 Evaluable Patients with Right-Sided Staphylococcus Aureus Endocarditis. \$32,000.

1999 - 00

Bayer Corporation. Bay 12-8039 Pneumonia Study: Prospective, Randomized, Double-Blind, Multicenter Comparison of the Safety and Efficacy of Sequential (IV to PO) BAY 12-Sequential Trovan I.V./Trovan Tablets 200/200mg QD for 7-14 Days in the Treatment of Patients with Community Acquired Pneumonia. \$71,360.

1999

Pharmacia & Upjohn. Linezolid Skin & Soft Tissue Infection Study. Linezolid vs. Oxacillin Sodium/Dicloxacillin for the Treatment of Complicated Skin and Soft Tissue Infections. \$120,000.

1999

Schering-Plough Research Institute. Ziracin Gram Infections Study: Randomized Double-Blind, Comparative Phase II Study of the Safety and Efficacy of Ziracin versus Vancomycin in the Treatment of Serious Gram-Positive Infections. \$38,500.

1998

Schering-Plough Research Institute. Ziracin Pneumonia Study: Randomized, Double-Blind Comparative Phase III Study of Ziracin (SCH 27899) versus Ceftriaxone in the Treatment of Moderate of Severe Acute Bacterial Pneumonia due to S. pneumoniae. \$53,940.

1997 - 98

Pharmacia & Upjohn. Linezolid in the Treatment of Community Acquired S. Pneumonia. \$10,000.

1997 - 98

Pharmacia & Upjohn. Linezolid in the Treatment of Skin/Soft Tissue Infections: An Open-Label, Dose Comparative Phase II Study of Intravenous Therapy With Optional Oral Continuation. \$49,938.

1997 – 98

Rhone-Poulenc Rorer. Pilot, Non-Comparative Study of Quinupristin/Dalfoprisitn (Synercid) in the treatment of Right-Sided S. Aureus Endocarditis in Intravenous Drug Abusers. \$28,000.

1996 – 98

Warner-Lambert/Parke-Davis A Double Blind, Prospective, Randomized, Multicenter Comparative Study of Clinafloxacin Versus a Ceftriaxone-Based Regimen in the Treatment of Community-Acquired Pneumonia. \$80,000.

1995 – 98

Warner-Lambert/Parke-Davis – An open lable, multi-center study of clinafloxacin in the treatment of infective endocarditis. \$70,000.

1995 - Present

Parke-Davis Pharmaceutical Research (Warner-Lambert Company). Clinafloxacin Endocarditis Study: An Open Label, Multicenter Study of Clinafloxacin in the Treatment of Infective Endocarditis. \$70,000.

1993 - 94

Miles Pharmaceutical - "Prospective, Double-blind, Controlled, Randomized, Multi-Center Comparison of the Safety and Efficacy of Intravenous Ciprofloxacin Versus Imipenem for the Treatment of Patients with the Sepsis Syndrome" - \$100,000.

- 1993 - 94 ICI Pharmaceuticals, Inc - "Multi-center Double-blind Comparative Study of Intravenous Meropenem and Imipenem for the Treatment of Nosocomial Lower Respiratory Tract Infections" - \$31,400.
- 1993 - 94 Amgen - "A Phase III Study of r-metHuG-CSF in the Treatment of Severe Community Acquired Pneumonia" - \$93,750.
- 1992 Miles Pharmaceutical - "Prospective, Controlled, Third Party-Blind, Randomized Study Comparing the Efficacy and Safety of Intravenous Ciprofloxacin with Intravenous Imipenem for the Treatment of Patients with Nosocomial Pneumonia" - \$62,399.87.
- 1991 - 94 Bristol Myers-Squibb - "Multi-investigation Comparative Study of the Safety and Efficacy of Cefepime and Ceftazidime in the Treatment of Hospitalized Patients with Septicemia" - \$191,794.00.
- 1989 Bristol Myers - "Comparative Study of Cefepime and Ceftazidime in the Treatment of Patients with Lower Respiratory Tract Infections and Serious Bacterial Infections" - \$445,527.
- 1989 - 94 Merrell Dow - "A Multi-center Randomized Blinded Comparative Study of Teicoplanin Dosing Regimens and Vancomycin in the Treatment of Endocarditis and Bacteremia of Non-cardiac Origin Caused by Gram-positive Bacteria" - \$118,512.
- 1989 Beecham Laboratories - "A Bacteriologically Controlled Study Comparing the Efficacy, Safety and Tolerance of Timentin and Cefoxitin as Early Empiric Treatment of Penetrating Abdominal Trauma" - \$118,376.
- 1987 Merrell Dow - "An Open Study of Teicoplanin in the Treatment of Intravenous Drug Abuse Associated Endocarditis Caused by Gram-positive Bacteria" - \$76,241.
- 1987 Merrell Dow - "A Randomized Blinded Comparative Study of Teicoplanin versus Vancomycin in the Treatment of Non-vascular Access Associated Bacteremia/Endocarditis Caused by Gram-positive Bacteria" - \$118,512.
- 1986 Miles Pharmaceutical - "Prospective, Controlled, Randomized, Double-Blind Comparisons of Intravenous Ciprofloxacin with Intravenous Ceftazidime in the Treatment of Selected Infections" - \$125,880.
- 1986- 87 Lederle - "A Multi-Clinic Randomized Double-blind Comparative Study of Piperacillin and Ceftazidime in the Treatment of Hospitalized Adults with Acute Lower Respiratory Infections" - Initial grant with 20 patients \$32,000.
- 1985- 86 Lederle - "Parenteral Piperacillin Sodium in Patients with Renal Insufficiency and/or Lower Respiratory Infections" - \$32,000.
- 1984- 85 Beecham Laboratories - "Parenteral Timentin Therapy for Intra-abdominal and

- Gynecological Infections - \$106,480.
- 1984- 85 Hoffman-LaRoche - "Ceftriaxone for the Parenteral Therapy of Bacterial Meningitis in Adults" - \$11,393.40.
- 1984 Roerig-Pfizer - "The Usefulness of Prophylactic Cefoperazone Therapy During Endoscopic Retrograde Cholangiopancreatography".
- 1984- 85 Roche Laboratories - "Coumermycin Use in the Rabbit Model of Methicillin-Resistant Bacterial Endocarditis" - \$10,000.
- 1984- 85 Eli Lilly Company - "Pharmacokinetic Dosing Consideration in Patients Receiving High Dose Aminoglycoside for Gram Negative Endocarditis" - \$10,000.
- 1984 Lederle Laboratories - "The Usefulness of Prophylactic Piperacillin Therapy during Endoscopic Retrograde Cholangiopancreatography (ERCP)" - \$7,260.
- 1983- 84 Harper Hospital Medical Trust Fund - WSU Fund for Medical Research and Education - "Proposal for Further Studies of Experimental Herpes Simplex Virus, Type I, Encephalitis" - \$15,000.
- 1983- 85 Upjohn Corporation - "Clindamycin vs Penicillin in the Treatment of Lung Abscess" - \$50,000.
- 1981- 83 American Hoechst Corporation - "Encephalitis Research" - \$20,000.

CLINICAL TRIAL ACTIVITIES (in progress or pending final contract approval)

Investigator initiated Study: Combination Therapy for MRSA Bacteremia and Endocarditis: A Multicenter Study Forest Research Institute, Inc. Award \$719,427. Awaiting final contract approval

ORIGINAL OBSERVATIONS IN REFEREED JOURNALS:

1. Levine DP, Lauter CB and Lerner AM: Simultaneous serum and cerebrospinal fluid antibodies in herpes simplex virus encephalitis. *J Am Med Assoc* 240:356-360, 1978.
2. Levine DP and Lerner AM: The clinical spectrum of *Mycoplasma pneumoniae* infections (with special emphasis upon pathologic physiology and complications). *Med Clin North Am* 62:961-978, 1978.
3. Champney KJ, Levine DP, Levy HB, and Lerner AM: Studies of a modified polyribonucleosinic-polyribocytidylic acid complex: sustained interferonemia and its physiological associates in humans. *Infection and Immunity* 25:831-837, 1979.

4. Levine DP and Tintinalli JE: Miliary tuberculosis. *JACEP* 8:485-489, 1979.
5. Levine DP and Lerner AM: Herpes simplex encephalitis. *N Engl J Med* 302:867-868, 1980.
6. Cushing RD, Jui J, Levine DP, Chadzynski L, and Nolan DC: Community-acquired methicillin-resistant *Staphylococcus aureus* infections - Michigan MMWR 30:185-187, 1981.
7. Levine DP and Traber PG: Vancomycin ototoxicity in a patient with normal renal function: a case report and review of the literature. *Ann Intern Med* 95:458-460, 1981.
8. Levine DP, Cushing RD, Jui J, and Brown WJ: Community acquired methicillin-resistant *Staphylococcus aureus* bacterial endocarditis in the Detroit Medical Center. *Ann Intern Med* 97:330-339, 1982.
9. Levine DP, and Lerner AM: Experimental herpes simplex virus, Type I, encephalitis; relationship of fever, interferon, virus and antibody. *J Infect Dis* 149 (6):1025, 1984.
10. Chandrasekar PH, Price S, Levine DP: In vitro evaluation of cefpirome (HR 810), teicoplanin and 4 other antimicrobials against enterococci. *Journal of Antimicrobial Chemotherapy*, 16:179-182, 1985.
11. Kiel RJ, Chandrasekar PH, and Levine DP: Unusual complications of Hickman catheters. *Infections in Surgery*, 5:465-466, 1986.
12. Chandrasekar PH, Arathoon E, Levine DP: Infection due to *Achromobacter xylosoxidans*. *Infection* 14(6): 279-282, 1986.
13. Crane LR, Levine DP, Zervos MJ, and Cummings G: Bacteremia in narcotic addicts in the Detroit Medical Center: I. Microbiology, Epidemiology and Clinical Correlates. *Rev Inf Dis*, 8(3):364-373, 1986.
14. Levine DP, Crane LR, Zervos MJ: Bacteremia in narcotic addicts in the Detroit Medical Center: II. Infectious endocarditis; A prospective comparative study. *Rev Inf Dis*, 8(3):374-396, 1986.
15. Unowsky J, Chandrasekar PH, DeLorenzo W, and Levine DP: The *in vitro* and *in vivo* activity of coumermycin, vancomycin, fusidic acid, and cotrimoxazole against methicillin-resistant *Staphylococcus aureus* strains isolated at the Detroit Receiving Hospital. *Chemotherapy* 32:499-505, 1986.
16. Rybak M, Boike S, Levine DP, and Erickson S: Clinical use and toxicity of high dose tobramycin in patients with pseudomonal endocarditis. *J Antimicrob Chemotherapy*, 17:115-120, 1986.
17. McCray E and the Cooperative Needlestick Surveillance Group: Occupational risk of the Acquired Immunodeficiency Syndrome among health care workers. *N Engl J Med*, 314:1127-1132, 1986.
18. Levine DP, Komshian SV, Chandrasekar PH: Adenovirus pneumonia in healthy adults. *Heart & Lung*, 16(2):146-150, 1987.

Donald P. Levine, M.D.

Curriculum Vitae

Page 13 of 33

19. Chandrasekar PH, Levine DP, Price S and Rybak MJ: Comparative efficacies of imipenem-cilastatin and vancomycin in experimental aortic valve endocarditis due to methicillin resistant *Staphylococcus aureus*. J Antimicrob Chemother, 21:461-469, 1988.
20. Levine DP and Wilson RF: Treatment of penetrating abdominal trauma and gynecologic infections. J Repro Med, 33(Suppl 6):598-602, 1988.
21. Levine DP, McNeil P, Lerner SA: Randomized, double-blind comparative study of intravenous ciprofloxacin versus ceftazidime in the treatment of serious infections. Rev Inf Dis, 2 (Supl 5):S1173-1174, 1989.
22. Levine DP, McNeil P, and Lerner SA: Randomized, double-blind comparative study of intravenous ciprofloxacin versus ceftazidime in the treatment of serious infections. Amer J Med 87(Suppl 5A):S160-S163, 1989.
23. Rybak MJ, Lerner SA, Levine DP, Albrecht LM, McNeil PL, Thompson GA, Kenny MT, and Yuh L: Teicoplanin pharmacokinetics in intravenous drug abusers being treated for bacterial endocarditis. Antimicrob Agents Chemother, 35(4):696-700, 1991.
24. Levine DP, Fromm BS, and Reddy BR: Slow response to vancomycin or vancomycin plus rifampin therapy among patients with methicillin-resistant *Staphylococcus aureus* endocarditis. Ann Intern Med, 115:674-680, 1991.
25. Moore RD, Lerner SA and Levine DP: Nephrotoxicity and ototoxicity of aztreonam versus aminoglycoside therapy in seriously ill nonneutropenic patients. J Infect Dis, 165:683-688, 1992.
26. Johnson DR, Love-Dixon MA, Brown WJ, Levine DP, Downes FP, and Hall WN: Delayed detection of an increase in resistant *Acinetobacter* at a Detroit hospital. Infect Control Hosp Epidemiol, 13:394-398, 1992.
27. Levine DP, Schwartz R, and Palmer D: Cefepime versus ceftazidime for the treatment of serious bacterial infections: Double-blind, randomized, comparative trial. Am J Med, 95 (Suppl 4A):41-47, 1993.
28. Fink MP, Snyderman DR, Niederman MS, Leeper KV, Jr., Johnson RH, Heard SO, Wunderink RG, Caldwell JW, Schentag JJ, Siami GA, Zameck RL, Haverstock DC, Reinhart HH, Echols RM, and the Severe Pneumonia Study Group: Treatment of severe pneumonia in hospitalized patients: Results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrobial Agents Chemother, 38;3:547-557, 1994.
29. Randich CA and Levine DP: Urinary tract infections. Clin Infect Chemother 1:46-49, 1995.
30. James JK, Palmer SM, Levine, DP and Rybak MJ: Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections. Antimicrob Agents Chemother 40 (3): 696-700, 1996.
31. Przybylski KG, Rybak MJ, Martin PR, Weingarten CM, Zaran FK, Stevenson JG and Levine DP: A Pharmacist initiated Program of intravenous oral antibiotic Conversion. Pharmacotherapy 17:271-276, 1997.

Donald P. Levine, M.D.

Curriculum Vitae

Page 14 of 33

32. Weingarten CM, Rybak MJ, Brown WJ, Jahns BE, Stevenson JG and Levine DP: An Evaluation of *Acinetobacter baumannii* infections and Antimicrobial Treatment Patterns in an Urban Teaching Hospital. *Pharmacotherapy* 19:1080-1085, 1999.
33. Kak V, Levine DP: Community-Acquired Methicillin-Resistant *Staphylococcus aureus* Infections Where do we go from here? *Clinical Infectious Diseases* 29:801-802, 1999.
34. Douglas MA and Levine DP: Hallucinations in an Elderly Patient Taking Recommended Doses of Cyclobenzaprine. *Arch Intern Med* 160:1373, 2000.
35. Tam VH, McKinnon PS, Levine DP, Brandel SM and Rybak MJ: Once-Daily Aminoglycoside in the Treatment of *Enterococcus faecalis* Endocarditis. *Pharmacotherapy* 20(9):1116-1119, 2000.
36. Kanno M, Pore G and Levine DP: Recurrent Group B Streptococcus Bacteremia Associated with Menstruation. *Infect Dis Clin Practice*. 10:103-105, 2001.
37. Brown PD and Levine DP: Infections in Injection Drug Users. *Infect Dis Clin N Am* 16 2002; 16: xiii-xiv.
38. Brown PD and Levine DL: Infective Endocarditis in the Injection Drug User. *Infect Dis Clin N Am* 2002; 16:645-665.
39. Levine DP and Kaur J: "Cytomegalovirus Induced Gingival hyperplasia. *Clin Infect Dis* 2003;37:e44-6.
40. Levine DP, Holley HP, Eiseman I, Willcox P and Tack K: Clinafloxacin for the Treatment of Bacterial Endocarditis. *Clin Infect Dis*; 2004;38:620-631.
41. Fowler VG, Jr., Miro JM, Hoen B, Cabell CH, Abrutyn E, Rubinstein E, Corey GR, Spelman D, Bradley SF, Barsic B, Pappas PA, Anstrom KJ, Wray D, Fortes CQ, Anguera I, Athan E, Jones P, van der Meer JT, Elliott TS, Levine DP, Bayer AS; ICE Investigators: *Staphylococcus aureus* endocarditis: a consequence of medical progress. *JAMA* 2005;293:3012-3021.
42. Levine DP. Vancomycin: A History. *Clin Infect Dis*. 2006; 42 Suppl 1:S5-12.
43. Fowler VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest G, Fatkenheuer G, Gareca M, Rehm SJ, Brod HR, Tice A and Cosgrove SE for the *S. aureus* Endocarditis and Bacteremia Study Group. Daptomycin versus Standard Therapy for *Staphylococcus aureus* Bacteremia and Endocarditis. *N. Engl J Med*. 2006;355:653-665.
44. Ebright JR, Alam E, Ahmed H, Tucker R, Abrams J and Levine D. Splenic Infraction and Abscess in the Setting of Infective Endocarditis: A Review of Diagnostic Methods and Management. *Infect Dis Clin Pract*. 2007;15:17-21.
45. Lodise TP Jr, McKinnon PS, Levine DP, Rybak MJ. Impact of Empirical Therapy Selection on Outcomes of Intravenous Drug Users with Methicillin Susceptible *Staphylococcus aureus* Infective Endocarditis. *Antimicrob Agents Chemother*. 2007;51:3731-3733.

Donald P. Levine, M.D.

Curriculum Vitae

Page 15 of 33

46. Rupp ME, Holley HP, Jr., Lutz J, Dicpinigaitis PV, Woods C, Levine DP, Veney N, Fowler VG, Jr, for the Altastaph adult clinical trials group. A phase II, randomized, multicenter, double-blind, placebo-controlled, trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in the treatment of Staphylococcus aureus bacteremia. *Antimicrob Agents Chemother.* 2007;51:4249-4254.
47. Levine DP, Lamp KC. Daptomycin in the treatment of patients with infective endocarditis: experience from a registry. *Am J Med.* 2007;120 (Suppl 1): S28-S33.
48. Morpeth S, Murdoch D, Cabell, CH, Karchmer AW, Pappas P, Levine D, Nacinovich R, Tattevin P, Fernandez-Hidalgo N, Dickerman S, Bouza E, del Rio A, Lejko-Zupanc T, de Oliveira RA, Iarussi D, Klein J, Chirouze C, Bedimo R, Corey GR, Fowler VG Jr. Non-HACEK Gram-negative bacillus endocarditis. *Ann Intern Med.* 2007;147:829-835.
49. Lalani T, Boucher HW, Cosgrove SE, Fowler VG, Kanafani ZA, Vigliani GA, Champion M, Abrutyn E, Levine DP, Price CS, Rehm SJ, Corey RG, Karchmer AW. Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with *Staphylococcus aureus* bacteremia. *J Antimicrob Chemother.* 2008;61:177-182
50. Levine DP. Vancomycin: Understanding Its Past and Preserving Its Future. *South Med J* 2008;101:284-291.
51. Chu V, Woods CW, Miro JM, Hoen B, Cabell CH, Pappas PA, Federspiel J, Athan E, Stryjewski ME, Nacinovich F, Marco F, Levine DP, Elliott TS, Fortes CQ, Tornos P, Gordon DL, Utili R, Delahaye F, Corey GR, Fowler VG, Jr. Emergence of Coagulase Negative Staphylococci as a Cause of Native Valve Endocarditis. *Clin Infect Dis.* 2008;46:232-242.
52. Baddley JW, Benjamin DK Jr, Patel M, Miró J, Athan E, Barsic B, Bouza E, Clara L, Elliott T, Kanafani Z, Klein J, Lerakis S, Levine D, Spelman D, Rubinstein E, Tornos P, Morris AJ, Pappas P, Fowler VG Jr, Chu VH, Cabell C; The International Collaboration on Endocarditis—Prospective Cohort Study Group (ICE-PCS). Candida Infective Endocarditis. *Eur J Clin Microbiol Infect Dis.* 2008;27:519-529.
53. Levine DP. Therapy for Community-Associated MRSA Infections: Antibiotics and More. *Clinical Updates in Infect Dis.* 2008;11:1-6.
54. Rehm, Susan; Boucher, Helen; Levine, DP; Champion, Marilyn; Eisenstein, Barry; Vigliani, Gloria; Corey, G; Abrutyn, Elias. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. *J Antimicrob Chemother.* 2008;62:1413-1421.
55. Levine DP, Rybak MJ. Special report: guidelines in the treatment of methicillin-resistant Staphylococcus aureus. *Infectious Disease Special Edition.* 2008;11:1-8.
56. Levine DP. Clinical experience with daptomycin: bacteraemia and endocarditis. *J Antimicrob Chemother* 2008 62 Suppl 3:iii35-iii39.
57. Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, Dalovisio JR, Levine DP. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the

- American Society of Health System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. *Am J Health Syst. Pharm.* 2009;66:82-98.
58. Raygada JI, Levine DP. Managing CA-MRSA Infections: Current and Emerging Options. *Infect Med.* 2009;26:49-58.
 59. Cosgrove SE, Vighiani GA, Campion M, Fowler VG, Abrutyn E, Corey GR, Levine DP, Rupp ME, Chambers HF, Karchmer AW, Boucher HW. Initial Low-Dose Gentamicin for *Staphylococcus aureus* Bacteremia and Endocarditis is Nephrotoxic. *Clin Infect Dis* 2009;48:713-721.
 60. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC Jr, Craig WA, Billeter M, Dalovisio JR, Levine DP. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. *Pharmacotherapy.* 2009 Nov;29(11):1275-9. Review.
 61. Levine DP. Prevention of Catheter-related Infection: Evidence-based Medicine. *Curr Infect Dis Rep.* 2009;11:255-256.
 62. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, Dalovisio JR, Levine DP. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. *Clin Infect Dis.* 2009 Aug 1;49(3):325-7. Erratum in: *Clin Infect Dis.* 2009 Nov 1;49(9):1465.
 63. Bachour K, Zmily H, Kizilbash M, Awad K, Hourani R, Hammad H, Sobel JD, Ghali JK, Levine D, Afonso L. Valvular perforation in left-sided native valve infective endocarditis. *Clin Cardiol.* 2009 ;32:E55-62.
 64. Kanafani ZA, Kourany WM, Fowler VG Jr, Levine DP, Vighiani GA, Campion M, Katz DE, Corey GR, Boucher HW Clinical characteristics and outcomes of diabetic patients with *Staphylococcus aureus* bacteremia and endocarditis. *Eur J Clin Microbiol Infect Dis.* 2009;28(12):1477-82.
 65. Saydain G, Singh J, Dalal B, Yoo W, Levine DP. Outcome of patients with injection drug use-associated endocarditis admitted to an intensive care unit. *J Crit Care.* 2010;25:248-253.
 66. Kosmidis C, Levine DP. Daptomycin: pharmacology and clinical use. *Expert Opin Pharmacother.* 2010;11:615-625.
 67. Kanafani Z, Boucher H, Fowler V, Cabell C, Hoen B, Miro J, Lalani T, Vighiani G, Campion M, Corey R, Levine D. Daptomycin compared to standard treatment of native valve endocarditis. *Enferm Infecc Microbiol Clin.* 2010;28:498-503.
 68. Levine DP. Clinical Trial Report: Is it Safe to Continue Anticoagulation Therapy in Patients with Infective Endocarditis? *Curr Infect Dis Rep.* 2010;12:231-233.

69. Lui C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine, DP, Murray BE, Rybak MJ, Talan DA, Chambers HF. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant *Staphylococcus Aureus* Infections in Adults and Children. *Clin Infect Dis* 2011;52:1-38.
70. Kullar R, Davis SL, Levine DP, Zhao JJ, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ. A Large Multi-Center Study of High-Dose Daptomycin for Complicated Gram-Positive Infections. *Pharmacotherapy* 2011;31:527-536.
71. Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of Vancomycin Exposure on Outcomes in Patients with Methicillin-Resistant *Staphylococcus aureus* Bacteremia: Support for Consensus Guidelines Suggested Targets. *Clin Infect Dis* 2011;52:975-981.
72. Lui C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine, DP, Murray BE, Rybak MJ, Talan DA, Chambers HF. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant *Staphylococcus Aureus* Infections in Adults and Children: Executive Summary. *Clin Infect Dis* 2011;52:285-292.
73. Kullar R, Davis SL, Levine DP, Zhao JJ, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ. High Dose Daptomycin for Treatment of Complicated Gram-Positive Infections: a Large Multicenter, Retrospective Study. *Pharmacotherapy* 2011;31:527-536.
74. Levine DP, Lanfranco OA. MRSA Guidelines: a Matter of Time. *Expert Rev Anti Infect Ther*. 2011;9:495-496.
75. Levine DP. Synergy: a Cautionary Tale. *Curr Infect Dis Rep*. 2011;13:303-304.
76. **Casapao AM, Steed ME, Levine DP, Rybak MJ. Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection. *Expert Opin Pharmacother* 2012;13:1177-1186.**
77. **Kullar R, Davis SL, Kaye KS, Levine DP, Pogue JM, Rybak MJ. Implementation of an Antimicrobial Stewardship Pathway with Daptomycin for Optimal Treatment of Methicillin-Resistant *Staphylococcus aureus* Bacteremia. *Pharmacotherapy* 2013;33:3-10.**
78. **Rojas, G, Levine DP. Transient *Staphylococcus aureus* Bacteremia in an Urban Teaching Hospital. *Infect Dis Clin Practice* 2013;21:330-37.**
79. **Casapao AM, Kullar R, Davis SL, Levine DP, Zhao J, Potoski B, Goff D, Crank C, Segreti J, Sakoulas G, Cosgrove S, Rybak MJ. Multicenter Study of High-Dose Daptomycin for Treatment of Enterococcal Infections. *Antimicrob Agents Chemother* 2013;57:4190-4196 .**
80. **Kullar R, Casapao A, Davis S, Levine DP, Zhao J, Crank C, Segreti J, Sakoulas G, Cosgrove S, Rybak M. A Multicenter Evaluation of the Effectiveness and Safety of High-Dose Daptomycin for the Treatment of Infective Endocarditis. *J Antimicrob Chemother* 2013;68:2921-2926.**

81. **Levine DP. Is an Aminoglycoside Still Required for the Treatment of Enterococcal Endocarditis? Curr Infect Dis Rep. 2013;15:353-355.**
82. **Casapao AM, Davis SL, McRoberts JP, Lagnf AM, Patel S, Kullar R, Levine DP, Rybak MJ. Evaluation of Vancomycin Population Susceptibility Analysis Profile as a Predictor of Outcomes for Patients with Infective Endocarditis Due to Methicillin-Resistant *Staphylococcus aureus*. Antimicrob Agents Chemother 2014;58:4636-4641.**

EDITORIALS:

1. Levine DP: Gram-positive infections: Impact of emerging resistance on therapeutic management. Infections in Medicine Supplement, page 3 & 26, June 1994.
2. Kak V, Levine DP: Community-Acquired Methicillin-Resistant *Staphylococcus aureus* Infections Where do we go from here? Clinical Infectious Diseases 29:801-802, 1999.
3. Levine D. Daptomycin for Infective Endocarditis. Current Infectious Disease Reports. 2006;8:263-264.

LETTERS:

1. Levine DP, Lerner AM: Herpes simplex encephalitis. N Engl J Med, 302:867-868, 1980.
2. Lerner AM, Levine DP, Reyes, MP: Two cases of herpes simplex virus encephalitis in the same family. N Engl J Med 308(24):1481, 1983.

BOOKS and PERIODICALS EDITED:

1. Levine DP, Sobel JD: Infections in intravenous drug abusers. Oxford University Press, New York, NY, 1991.
2. Editorial Board for: Wilson RF and Janning SW: Handbook of antibiotic therapy for surgery-related infections, Third Edition, Scientific Therapeutics Information, Inc., Springfield, NJ, 1994.
3. Brown PD, Levine DP: Editors, Infections in injection drug users. Infectious Disease Clinics of North America: 2003; Volume 16. W.B. Saunders Company, Philadelphia, 2002.
4. Levine D, Section Editor, Cardiovascular Infections in Current Infectious Disease Reports, Volume 8, Current Science Inc. Philadelphia, PA, 2006.
5. Levine D, Section Editor, Cardiovascular Infections in Current Infectious Disease Reports, Volume 9, Current Medicine Group LLC, Philadelphia, PA, 2007.
6. Levine D, Section Editor, Cardiovascular Infections in Current Infectious Disease Reports,

- Volume 10, Current Medicine Group LLC, Philadelphia, PA, 2008.
7. Levine D, Section Editor, Cardiovascular Infections in Current Infectious Disease Reports, Volume 11, Current Medicine Group LLC, Philadelphia, PA, 2009.
 8. Levine D, Section Editor, Cardiovascular Infections in Current Infectious Disease Reports, Volume 12, Current Medicine Group LLC, Philadelphia, PA, 2010.
 9. Levine D, Section Editor, Cardiovascular Infections in Current Infectious Disease Reports, Volume 13, Current Medicine Group LLC, Philadelphia, PA, 2011.
 10. **Levine D, Section Editor, Cardiovascular Infections in Current Infectious Disease Reports, Volume 14, Current Medicine Group LLC, Philadelphia, PA, 2012.**
 11. **Levine D, Section Editor, Cardiovascular Infections in Current Infectious Disease Reports, Volume 15, Current Medicine Group LLC, Philadelphia, PA, 2013.**
 12. **Levine D, Section Editor, Cardiovascular Infections in Current Infectious Disease Reports, Volume 16, Current Medicine Group LLC, Philadelphia, PA, 2014.**

BOOKS CHAPTERS:

1. Lerner AM, Williams B, Levine DP and Crane LR: Viral Encephalitis. In: Kass EH, Platt E, Eds. Current Therapy in Infectious Disease, BC Decker, CV Mosby, 133-157, 1983.
2. Levine DP: Antiviral Chemotherapy In: Pharmacology in Medicine, SN Pradham, RP Michael, and SN Dutta (Editors), SP Press, 825-836, 1986.
3. Levine DP, Sobel JD: Infections in intravenous drug abusers. In: Principles and Practice of Infectious Disease, Fourth Edition. GL Mandell, JE Bennett and R Dolin (Editors), Churchill and Livingstone Publishers, New York, NY, Vol 2;2696-2709, 1994.
4. Lundstrom TS, Levine DP: Disk Space Infection. In: Diagnosis and Management of Bone Infections, Juarequi LE, (Editor), Marcel Dekker, Inc., 151-166, 1995.
5. Arbulu A, Gellman S, Levine DP and Stephenson LW: Endocarditis: Multidisciplinary Approach to Medical Treatment. Futura Publishers, Mt. Kisco, NY, 1998.
6. Levine DP, Brown PD: Infections in Injection Drug Users. In: Principles and Practice of Infectious Disease, Fifth Edition. GL Mandell, JE Bennet and R Dolin (Editors), Churchill and Livingstone Publishers, New York, NY, 2;3112-3126, 2000.

7. Levine DP: Infective Endocarditis. In: Conn's Current Therapy, Houston, TX, pg. 313-319, 2002.
8. Brown PD and Levine DP: Infective Endocarditis in the Injection Drug User. In: Infectious Disease Clinics of North America. W.B. Saunders, Philadelphia, 2002;16:645-666.
9. Levine DP: Endocarditis. In: Kruse JA, Carlson RW, Fink MP, Eds. Saunders Manual of Critical Care Practice, Philadelphia, PA, 105;379-383, 2003.
10. Levine DP: Gram Positive Infections. In: Kruse JA, Carlson RW, Fink MP, Eds. Saunders Manual of Critical Care Practice, Philadelphia, PA, 93;327-332, 2003.
11. Levine DP: Gram Negative Infections. In: Kruse JA, Carlson RW, Fink MP, Eds. Saunders Manual of Critical Care Practice, Philadelphia, PA, 94;333-338, 2003.
12. Levine DP and Brown PD: Infections in Injection Drug Users. In: Principles and Practice of Infectious Disease, sixth Edition. GL Mandell, JE Bennet and R Dolin (Editors), Churchill and Livingstone Publishers, New York, NY, 2;3462-3476, 2005.
13. Ebricht J, Levine DP. Infective Endocarditis. In: Infectious Diseases, 2nd Edition, pgs 109-125. Tan JS, File TM, Salata RA, Tan MJ, eds. ACP Presss, Philadelphia, PA, 2008.
14. Levine DP and Brown PD: Infections in Injection Drug Users. In: Principles and Practice of Infectious Disease, seventh Edition. GL Mandell, JE Bennet and R Dolin (Editors), Churchill and Livingstone Publishers, New York, NY, 2:3875-3890, 2009.
15. **Levine D, Abreu-Lanfranco O. Endocarditis IVDA in Clinical Support: Infectious Diseases, edited by Southwick FS, Hirschel B, Karchmer AW, Kauffman C, Wenzel RP. 2013. Decision Support in Medicine, LLC. Wilmington, DE.**
16. **Levine DP and Brown PD: Infections in Injection Drug Users. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Disease, Eighth Edition. JE Bennett, R Dolan and MJ Blaser. Elsevier Saunders, Philadelphia, PA, 2:3475-3491, 2014.**

INVITED AND/OR REFEREED INTERNATIONAL OR NATIONAL MEETINGS (last five years):

1. Levine DP, Ebricht J. Detection and Management of Splenic Abscesses in Patients with Endocarditis. 7th International Symposium on Modern Concepts in Endocarditis and Cardiovascular Infections. Chamonix Mont-Blanc, France, June 26 - 28, 2003.
2. Rupp ME, Lutz J, Dicipinigitis P, Woods C, Levine DP, Holley HP. Trial of *Staphylococcus aureus* Capsular Polysaccharide (CPS) Immune Globulin in Subjects with *S. aureus* Bacteremia and Persistent Fever, Abstract LB-6, LB 14. 43rd Annual Meeting, Infectious Diseases Society of America. San Francisco, California, October 6-9, 2005.
3. Morpeth SC, Cabell CH, Murdoch DR, Miro JM, Abrutyn E, Hoen B, Karchmer AW, Levine DP, Pappas PA, Corey GR, Fowler V, International Collaboration on Endocarditis Study Group.

Donald P. Levine, M.D.

Curriculum Vitae

Page 21 of 33

- Native Valve Endocarditis (NVE) Due to Aerobic Gram-Negative Nonfastidious Rods: Report of 41 Episodes from the International Collaboration on Endocarditis Merged (ICE-MD) and Prospective (ICE-PS) Databases. Abstract 347. 43rd Annual Meeting, Infectious Diseases Society of America. San Francisco, California, October 6-9, 2005.
4. Levine DP, Lamp KC. Endocarditis Treated with Daptomycin (DAP): Experience from a Registry. Abstract 359. 43rd Annual Meeting, Infectious Diseases Society of America. San Francisco, California, October 6-9, 2005
 5. Fowler V, Cosgrove S, Abrutyn E, Boucher H, Chambers H, Corey G, Demeyer I, Filler S, Levine D, Link A, Rupp M, Karchmer A. Daptomycin vs. Standard Therapy for *Staphylococcus aureus* Bacteremia (SAB) and Infective Endocarditis (SAIE). 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington D.D., December 16-19, 2005.
 6. Rehm S, Boucher H, Levine D, Champion M, Eisenstein B, Abrutyn E. Daptomycin vs. Vancomycin for Treatment of Methicillin-Resistant *Staphylococcus aureus* Bacteremia and Endocarditis. Abstract 139. 44th Annual Meeting, Infectious Diseases Society of America, Toronto, Ontario, Canada, October 12-15, 2006.
 7. Cosgrove S, Fowler V, Boucher H, Abrutyn E, Vigliani G, Corey R, Levine D, Rupp M, Chambers H. Initial Low-dose Gentamicin (GENT) in the Treatment of *S. aureus* Bacteremia (SAB) and Endocarditis (SAIE) is Nephrotoxic. Abstract 371. 44th Annual Meeting, Infectious Diseases Society of America, Toronto, Ontario, Canada, October 12-15, 2006
 8. Levine DP, Lamp KC. Safety and Efficacy of Daptomycin (DAP) for Endocarditis; Experience from a Registry. Abstract 401. 44th Annual Meeting, Infectious Diseases Society of America, Toronto, Ontario, Canada, October 12-15, 2006.
 9. Saydain G, Singh J, Levine DP. Outcome of Injection Drug Users with Infective Endocarditis Admitted to Intensive Care Unit. 9th International Symposium on Modern Concepts in Endocarditis and Cardiovascular Infection. Heidelberg, Germany, June 14-17, 2007.
 10. Levine DP, Lamp KC. Daptomycin Experience for *Staphylococcus aureus* Left-sided Endocarditis From a Registry. 9th International Symposium on Modern Concepts in Endocarditis and Cardiovascular Infection. Heidelberg, Germany, June 14-17, 2007.
 11. Levine DP, Lamp KC. Daptomycin Experience for Enterococcal Endocarditis From a Registry. 9th International Symposium on Modern Concepts in Endocarditis and Cardiovascular Infection. Heidelberg, Germany, June 14-17, 2007.
 12. Chu VH, Woods CW, Miro JM, Hoen B, Cabell CH, Pappas P, FederspiesJ, Athan E, Stryjewski ME, Nacinovich F, Marco F, Levine D, Elliott T, Fortes CQ, Tornos P, Gordon DL, Utili F, Delahaye D, Corey GR, Fowler VG, Jr, ICE-PCS Group, Predictors of Mortality in Coagulase-Negative Staphylococcal Native Valve Endocarditis. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17-20, 2007.

Donald P. Levine, M.D.

Curriculum Vitae

Page 22 of 33

13. Bhan R, Davis SL, Levine DP, Rybak MJ. What is Vancomycin Failure? It Depends on Your Definition. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October 25-28, 2008.
14. Levine DP, Hoffman-Roberts H, Brown J, Lamp KC. Outcomes with Daptomycin (DAP) for Infective Endocarditis (IE). 48th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October 25-28, 2008.
15. Kullar R, Davis SL, Crank CW, Segretti J, Cosgrove SE, Zhao J, Levine DP, Rybak MJ. Safety of high dose (HD DAP) for Gram-Positive Infections. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 12-15, 2009.
16. Kullar R, Davis SL, Pogue JM, Zhao JJ, Levine DP, Kaye KS, Rybak MJ. Evaluation of a Clinical Pathway for the Treatment of Methicillin-Resistant *Staphylococcus aureus* Bacteremia (MRSAB) with an MIC of > 1.0 mg/L to Vancomycin (VAN). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA September 12-15, 2010.
17. Kullar R, Davis SL, Levine DP, Rybak MJ. Vancomycin (VAN) Trough Concentrations and Outcomes in Patients with Methicillin-Resistant *Staphylococcus aureus* (MRSA) Endocarditis (IE). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA September 12-15, 2010.
18. Judd SL, Ahmad F, Levine DP. Spinal Epidural Abscess at Detroit Receiving Hospital. 48th Annual Meeting, Infectious Diseases Society of America, Vancouver, BC, Canada, October 21-24, 2010.
19. Rojas GE, Levine DP. Transient *Staphylococcus aureus* Bacteremia at an Urban Teaching Hospital. 48th Annual Meeting, Infectious Diseases Society of America, Vancouver, BC, Canada, October 21-24, 2010.
20. Mewada N, Mewada A, Levine DP. Significance of Troponin-I Value in Infective Endocarditis. 21st Annual Meeting, European Congress of Clinical Microbiology and Infectious Diseases/27th International Congress of Chemotherapy, Milan, Italy, May 9, 2011.
21. Kullar R, Steed M, Davis S, Cosgrove S, Potoski B, Goff D, Hasbun R, Crank C, Segreti J, Sakoulas G, Zhao J, Levine D, Rybak M. Safety and Clinical Outcomes of High-Dose Daptomycin for Enterococcal Infections. 21st Annual Meeting, European Congress of Clinical Microbiology and Infectious Diseases/27th International Congress of Chemotherapy, Milan, Italy, May 10, 2011.
22. Levine DP, Utili R, Durante-Mangoni E, Lamp KC, Yoon MJ, Chaves RL. Multinational Clinical Experience with High-Dose Daptomycin for the Treatment of Native Valve Endocarditis. 11th International Symposium on Modern Concepts in Endocarditis and Cardiovascular Infections. Cairns, Australia, July 25, 2011.
23. **Casapao AM, Davis SL, Levine DP, Zhao JJ, Potoski BA, Goff DA, Crank CW, Segreti J, Sakoulas G, Cosgrove S, Rybak MJ. High-Dose Daptomycin for Treatment of Enterococcal Infections, Multicenter, Retrospective Study. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA September 9-12, 2012**
24. **Davis SL, Rybak MJ, Vazquez JA, Hershberger E, Bernado P, Levine DP. Comparison of High Dose Daptomycin (DAP) and Dose Optimized Vancomycin (VAN) for MRSA**

- Bacteremia and Infective Endocarditis. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA September 9-12, 2012**
25. **Levine DP. Epidemiology and Outcomes of Patients with Infective Endocarditis (IE) who Undergo Splenectomy Prior to Valve Replacement Surgery. ID Week 2012, Joint Meeting of IDSA, SHEA, PIDS, San Diego, CA October 17-21, 2012.**
 26. **Claeys K, Casapao A, Pogue J, Saely S, Giuliano C, Hafeez W, Kaye K, Levine D, Davis S, Rybak M. Rapid Diagnostic Testing with GeneXpert Improves Enrolment in a Randomized Clinical Trial for Detection of Methicillin-Resistant *S. aureus* in Acute Bacterial Skin and Skin Structure Infections. 24th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, May 10-13, 2014.**
 27. **Fowler VG, Chambers H, Levine DP, Cole P, Jandourek A, Friedland HD, Corey GR. Interim Analysis of Ceftaroline Fosamil for the Treatment of *Staphylococcus aureus* Bacteremia. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, September 5-9, 2014.**

INVITED AND/OR REFEREED INTERNATIONAL OR NATIONAL PRESENTATIONS:

1. Presenter, Methicillin-resistant *Staphylococcus aureus* Endocarditis In Symposium on Methicillin-Resistant *Staphylococcus aureus*. 21st Inter-science Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, November 6, 1981.
2. Co-Chairman, Symposium on "Focus on Infection: 1989", Sponsored by Beecham Laboratories, Philadelphia, PA, April 14, 1989.
3. Chairman, Symposium on "Infections in Intravenous Drug Abusers", 16th International Congress of Chemotherapy, Jerusalem, Israel, June 11-16, 1989.
4. Presenter, Symposium on "Beta-Lactam Antibiotic Resistant Gram Positive Microbes", Topic "Treatment of Methicillin-Resistant *Staphylococcus aureus*", sponsored by Marion Merrell Dow, Inc., Naples, FL, November 6-7, 1992.
5. Panelist, Concensus Conference on "The Treatment of Infective Endocarditis", American Heart Association, Dallas, TX , December 5, 1992.
6. Program Chairman, Senior Infectious Disease Fellows Symposium, Naples, FL, December 7-9 1992.
7. Co-Chairman, Symposium on "Community Parenteral Therapy for Gram-positive Infections: Current Application and Future Needs, Lake Como, Italy, April 16-18, 1993.
8. Co-Chairman, Symposium on "Serious Infection: The Transition and Out-patient Therapy", New Orleans, LA, October 20, 1993.

9. Invited Speaker, "Infections in Injection Drug Users", Annual Meeting of the Tennessee Infectious Disease Society, Nashville, TN, August 23, 1997.
10. Grand Rounds, "Infections in Injection Drug Users", Mayo Clinic, Rochester, MN, September 8, 1997.
11. Presenter, Symposium: Infective Endocarditis, "Quinolones in Endocarditis" at 8th International Congress of Infectious Diseases, Boston, MA, May 17, 1998.
12. Invited Speaker, 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA., "Vancomycin Failure, What is It? What Can Be Done About It?" September 27-30, 2002.
13. Invited Speaker, "Vancomycin: Is It Still #1 After All These Years?" 6th Annual Internal Making a Difference Conference on Infectious Disease Pharmacotherapy, Lake Buena Vista, FL, May 2, 2003.
14. Grand Rounds, "Update on Infective Endocarditis" Vanderbilt University, Nashville Tennessee, January 27, 2004
15. Poster Presenter, 15th European Congress of Clinical Microbiology & Infectious Diseases Conference, Copenhagen, Denmark, April 2-5, 2005.
16. Invited Speaker, "Clinical Issues in the Treatment of *Staphylococcus aureus* Bacteremia and Infective Endocarditis", 8th Annual Make a Difference on Infectious Disease Pharmacotherapy, Carefree, AZ, May 12-15, 2005.
15. Invited Speaker, Cubicin Infectious Disease Advisory Board Meeting, Washington, DC, June 13-14, 2005
16. Invited Speaker, "Debate: Are bactericidal drugs the treatment of Choice for Infective Endocarditis? Pro", 8th International Symposium on Modern Concepts in Endocarditis and Cardiovascular Infections. Charleston, South Carolina, May 22-24, 2005.
17. Invited Symposium Moderator: "Old Drugs, New Applications", 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, December 16-19, 2005.
18. Invited Speaker, "When, How and When Not to Use Rifampin" 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, December 16-19, 2005
19. Grand Rounds, "Staphylococcal bacteremia and endocarditis." University of Kentucky, Lexington, KY, September 20, 2006
20. Invited Speaker, "Therapy for CA-MRSA Infections: Antibiotics and More." Symposium, Community-Associated Methicillin-Resistant *Staphylococcus aureus*: The Convergence of Resistance and Virulence. San Francisco, CA, September 27, 2006.
21. Invited Speaker, "Methicillin-resistant *Staphylococcus aureus* Endocarditis." 3rd International Symposium on Resistant Gram-Positive Infections. Niagara-on-the-Lake, Canada, October 11, 2006.

22. Invited Speaker, "Therapy for CA-MRSA Infections: Antibiotics and More." Symposium, Community-Associated Methicillin-Resistant *Staphylococcus aureus*: The Convergence of Resistance and Virulence. Toronto, Canada, October 11, 2006.
23. Invited Speaker, Infectious Diseases Grand Rounds, "MRSA Infections and Advances in Therapy", University of Kentucky, Lexington, Kentucky. January 4, 2007.
24. Invited Speaker, "Update in Staphylococcal Infections", Temple University, February 7, 2007.
25. Invited Speaker, "The Growing Problem of Staphylococcal Infections", University of Maryland, Baltimore, Maryland. February 22, 2007.
26. Invited Speaker, "Impact of the Increasing MRSA Threat on Treatment Outcomes in Bacteremia and Endocarditis." Symposium, Curbing the MRSA Epidemic. Los Angeles, California, February 24, 2007.
27. Infectious Disease Grand Rounds, "The Changing Face of Staphylococcal Infections", The University of Kansas, Kansas City, Kansas. March 20, 2007.
28. Invited Speaker, "MRSA Infections: Epidemiology, Clinical Patterns and Recent Advances in Treatment", Microbiology Department, Leicester Royal Infirmary, Leicester, England. May 8, 2007.
29. Invited Speaker, "Update on Staphylococcal Infections", Coventry, England. May 8, 2007.
30. Invited Speaker, "MRSA Infections: Recognizing The Clinical Pattern and Recent Treatment Advances", Department of Pathology, Walsgrave University Hospital, Walsgrave, Coventry, England. May 9, 2007.
31. Invited Speaker, "The Changing Face of Staphylococcal Infections", Royal College of Surgeons, London, England. May 9, 2007.
32. Invited Speaker, "Update on MRSA Infections: Epidemiology, Diagnosis and Treatment", Birmingham Hartlands Hospital, Birmingham, England. May 10, 2007.
33. Invited Speaker, "Recent Advances in Staphylococcal Infections", Swansea, Wales. May 10, 2007.
34. Invited Speaker, "Update in MRSA Infections", Welsh Microbiology Society, Cardiff, Wales. May 11, 2007.
35. Invited Speaker, "Catheter-related Infections", Infectious Diseases Society of Puerto Rico, San Juan, Puerto Rico. November 17, 2007.
36. Invited Speaker, "MRSA Infections", A Focus on Cyclic Lipopeptides in Serious Hospital Infections, Lisbon, Portugal. November 30, 2007.
37. Invited Speaker, "*Staphylococcus aureus* Bacteremia and Endocarditis", Lisbon, Portugal, March 13, 2008.
38. Invited Speaker, "*Staphylococcus aureus* Bacteremia and Endocarditis", American College of

- Physicians Annual Meeting, Washington, D.C., May 15, 2008.
39. Invited Speaker, “*Staphylococcus aureus* Bacteremia and Endocarditis”, Medical College of Georgia, Augusta, Georgia, May 20, 2008.
 40. Invited Speaker, ” “*Staphylococcus aureus* Bacteremia and Endocarditis”, Paris, France, June 7, 2008.
 41. Invited Keynote Speaker: “The Challenge From Bloodstream Infection and Infective Endocarditis.” Bloodstream Infection Summit Forum, Beijing, China, July 13, 2008.
 42. Invited Speaker: “Staphylococcal Bacteremia and Endocarditis.” Annual Meeting of the Venezuelan Infectious Disease Society, Valencia, Venezuela, November 13, 2008.
 43. Invited Speaker: “Glycopeptides: A History”. 11th Annual Western Pacific Congress on Chemotherapy and Infectious Diseases, Taipei, Taiwan, December 2, 2008.
 44. Invited Speaker. “MRSA, A moving target. Clinical implications”, MAD-ID symposium, Dallas, Texas, February 12, 2009.
 45. Invited Speaker: “MRSA Endocarditis”. International Staphylococcal Symposium, The Evolving MRSA Epidemic-and Response. Honolulu, Hawaii, March 13, 2009.
 46. Invited Speaker: “What to do when VRSA comes to town”. International Staphylococcal Symposium, The Evolving MRSA Epidemic-and Response. Honolulu, Hawaii, March 13, 2009.
 47. Invited Speaker. “MRSA, A moving target. Clinical implications”, MAD-ID symposium, Chicago, Illinois, April 16, 2009
 48. Invited Speaker: “Update on the Use of Lipopeptides in Endocarditis”. 10th International Symposium on Modern Concepts in Endocarditis and Cardiovascular Infections. Naples Italy, April 28, 2009.
 49. Invited Speaker: “*Staphylococcal aureus* Bacteremia and Endocarditis”, Madrid, Spain, June 18, 2009.
 50. Invited Speaker: “Staphylococcal infections” Conference: What’s at Risk. Palo Alto, California, December 16, 2009.
 51. Invited Speaker: “Skin and Skin-Structure Infections”, American College of Physicians, Minneapolis Convention Center, Minneapolis, MN, March 13, 2010.
 52. AOA Visiting Professor: “Things I Have Learned About Being a Doctor”, University of Arkansas AOA Dinner, Little Rock, Arkansas, April 14, 2010.
 52. Invited Speaker: “Skin and Skin-Structure Infections”, American College of Physicians, Baltimore Convention Center, Baltimore, MD, April 27, 2010.
 53. Invited Keynote Speaker: Gram-positive Infection Symposium: “The Challenge of *Staphylococcus aureus* Bloodstream Infections and Endocarditis”, Shanghai, China, July 13, 2010.

Donald P. Levine, M.D.

Curriculum Vitae

Page 27 of 33

54. Invited Keynote Speaker: Gram-positive Infection Symposium: “The Challenge of Staphylococcus aureus Bloodstream Infections and Endocarditis”, Hangzhou, China, July 14, 2010.
55. Invited Keynote Speaker: Gram-positive Infection Symposium: “The Challenge of Staphylococcus aureus Bloodstream Infections and Endocarditis”, Beijing, China, July 15, 2010.
56. Invited Keynote Speaker: Gram-positive Infection Symposium: “The Challenge of Staphylococcus aureus Bloodstream Infections and Endocarditis”, Guangzhou, China, July 17, 2010.
57. Invited Speaker: MRSA Infections: Clinical Problems, Diagnosis and Treatment. Infectious Disease Society of Puerto Rico, San Juan, Puerto Rico, March 22, 2011.
58. Invited Speaker: The MRSA Treatment Guidelines. China Medical Association Regional Meeting, Beijing, China, September 3, 2011.
59. Invited Speaker: The MRSA Treatment Guidelines. China Medical Association Regional Meeting, Zhengzhou, China, September 4, 2011.
60. Invited Speaker: The MRSA Treatment Guidelines. China Medical Association Regional Meeting, Chongqing, China, September 5, 2011.
61. Invited Speaker: The MRSA Treatment Guidelines. China Medical Association Regional Meeting, Urumqi, China, September 6, 2011.
- 62. Invited Speaker: Infectious Disease Grand Rounds. “Staphylococcal Infections”, Boone Hospital Center, Columbia, Missouri, March 22, 2012.**
- 63. Invited Speaker: Utilizing the ID Society MRSA Guidelines for critically ill patients. China Medical Association Regional Meeting, Beijing. China, May 16, 2012.**
- 64. Invited Speaker: Where Do We Stand One Year After the MRSA Guidelines. 6th Congress of Chinese Society of Critical Care Medicine. Jinan, Shandong Province, China, May 18, 2012**
- 65. Invited Speaker: Symposium and Round Table, Current Management of the MRSA Epidemic. Nanjing, China, May 20, 2012**
- 65. Invited Speaker: Roundtable: MRSA Guidelines in Current Practice. Jining, China, May 21, 2012**
- 66. Co-Chairman, Symposium: Emerging Current Challenges in Injection Drug Users. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA September 9-12, 2012**
- 67. Invited Speaker: “MRSA Infections”, Infectious Disease Grand Rounds, University of Oregon Health Sciences Center, Portland, OR, August 30, 2012**
- 68. Invited Speaker: Update on Endocarditis in Drug Users. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA September 9-12, 2012**
- 69. Invited Speaker: Vancomycin and MRSA infection. Pan-Asian Medical Institute Conference. Hangzhou, China, March 16, 2013.**

70. **Invited Keynote Speaker: The MRSA Guidelines. Osaka, Japan, June 1, 2013.**
71. **Invited Keynote Speaker: Use of the MRSA Guidelines. Tokyo, Japan, June 2, 2013.**
72. **Invited Speaker: The Challenge of MRSA Bacteremia and Endocarditis. Third Shanghai International Congress of Clinical Microbiology and Antimicrobial Chemotherapy. SICCMAC. Shanghai, China, August 24, 2013.**
74. **Invited Speaker: MRSA Bacteremia and Endocarditis in 2013. Infectious Disease Symposium, Peking Medical College Hospital, Beijing, China. August 28, 2013.**
75. **Invited Speaker: Improving Antimicrobial Stewardship Through Clinical Pathway Implementation. Making A Difference in Infectious Diseases Pharmacotherapy (MAD-ID), Orlando, Florida, May 30, 2014.**
76. **Invited Speaker: The MRSA Treatment Guidelines. Revised Treatment Guidelines-What's Coming. Making a Difference in Infectious Diseases Pharmacotherapy (MAD-ID), Orlando, Florida, May 31, 2014.**
77. **Invited Speaker: Antimicrobial Stewardship in 2014-A look at Benefits, Limitations, and Methods to Improve. 49th American Society of Hospital Pharmacists (ASHP), Anaheim, California, December 8, 2014.**

INVITED AND/OR REFEREED LOCAL/REGIONAL PRESENTATIONS

1. Presenter and Moderator, Eleventh Annual Advances In The Management of Infectious Diseases, Mackinac Island, MI, July, 1985.
2. Co-Chairman, Symposium on "Focus on Infection: 1989", Sponsored by Beecham Laboratories, Westin Hotel, Detroit, MI, April 13, 1989.
3. Program Chairman, Symposium of "Current Issues in Infectious Diseases", Detroit Institute of Art, Detroit, MI, October 23, 1991.
4. Lecturer, Alpha Omega Alpha Honor Medical Society, Beta Chapter of Michigan, Wayne State University, Detroit, MI, April 28, 1993.
5. Lecturer, 14th Annual Intensive Internal Medicine Review, OHEP Center for Medical Education, June 1994.
6. Lecturer, 15th Annual Intensive Internal Medicine Review, OHEP Center for Medical Education, June 1995.

7. Lecturer, 16th Annual Intensive Internal Medicine Review, OHEP Center for Medical Education, June 1996.
8. Lecturer, 17th Annual Intensive Internal Medicine Review, OHEP Center for Medical Education, June 3, 1997.
9. Lecturer, Emergency Medicine Residents and Faculty, William Beaumont Hospital, Royal Oak, MI, April 1, 1998.
10. Lecturer, 18th Annual Intensive Internal Medicine Review, OHEP Center for Medical Education, June 2, 1998.
11. Invited speaker: Vaccinations in Adults; Annual Collier Penberthy Thirlby Conference, Traverse City, MI, July 24, 1998.
12. Case Study Presentations, Infectious Diseases; Annual Collier Penberthy Thirlby Conference, Traverse City, MI, July 25, 1998.
13. Case Studies in Infectious Diseases, First Annual Conference for Infectious Diseases at Crystal Mountain, MI, August 1998.
14. Lecturer, OHEP Center for Medical Education Update in Internal Medicine: Infectious Disease Review, Southfield, MI, June 8, 1999.
15. Speaker, Annual Fall Update Infectious Diseases Symposium, Upper Valley Medical Center, Troy, OH, November 1999.
16. Speaker, Sepsis/Bacteremic Syndromes, Clinical Medicine III (PAS 703), Wayne State University College of Pharmacy and Allied Health Professions, Department of Physician Assistant Studies, January 21, 2000.
17. Case Studies in Infectious Diseases, Second Annual Conference for Infectious Diseases at Crystal Mountain, MI, July 2000.
18. Speaker, First Annual Internal Medicine Conference, Bay Harbor, Michigan, July 27-29, 2001.
19. Speaker, Second Annual Internal Medicine Conference, Bay Harbor, Michigan, Aug. 9-11, 2002.
20. Speaker, Third Annual Internal Medicine Conference, Bay Harbor, Michigan, July 25– 27, 2003.
21. Speaker, Fourth Annual Internal Medicine Conference, Bay Harbor, Michigan, July 30-Aug 1, 2004.
22. Speaker, *Staphylococcus aureus*: The Real Pathogenic Monster? Infectious Diseases Conference, Dayton, Ohio, March 23, 2005.
23. Speaker, Fifth Annual Internal Medicine Conference, Bay Harbor, Michigan, July 29-31, 2005
24. Speaker, Sixth Annual Update in Internal Medicine Conference, Bay Harbor, Michigan, “Emerging

- Disease: Bird Flu”, July 30, 2006.
25. Invited Speaker, Fall 2006 Pharmacy CE Symposium: Emerging Trends in the Treatment of Infectious Disease. “Changing Face of *Staphylococcus aureus* infections.” Detroit, MI, September 15, 2006
 26. Invited Speaker, 7th Annual Norman Krieger Conference on Geriatric Medicine. “Bird Flu”, Novi, Michigan, November 1, 2006
 27. Invited Speaker, Infectious Disease Conference, Henry Ford Hospital, Detroit, Michigan, “Management of MRSA Endocarditis”, November 13, 2006
 28. Invited Speaker, “The Current Status of MRSA Infections”, Infectious Disease Conference, Providence Hospital, Southfield, Michigan. January 11, 2007.
 29. Invited Speaker, “MRSA Endocarditis”, 11th Annual Infectious Diseases and Critical Care Symposium: A New Frontier, Dearborn, Michigan. January 26, 2007.
 30. Invited Speaker, “Treatment of MRSA Infections”, MRSA: The New Challenge. Epidemiology and Treatment sponsored by Wayne State University. Novi, Michigan. June 2, 2007.
 31. Speaker, Seventh Annual Update in Internal Medicine Conference, Bay Harbor, Michigan, “Case study in a patient with sepsis”, August 3, 2007.
 32. Invited Speaker, “MRSA Infections, The Latest Infectious Disease Crisis”, Flint Infectious Disease Society Annual Meeting, April 9, 2008.
 35. Invited Speaker, “MRSA: Meeting the Clinical Challenge” Centers of Excellence Regional Meeting, Birmingham, Michigan, April 15, 2008.
 36. Speaker, Eighth Annual Update in Internal Medicine Conference, Bay Harbor, Michigan, “The latest Infectious Disease Crisis”, August 2, 2008.
 37. Speaker, Ninth Annual Update in Internal Medicine Conference. “Update in Infectious Diseases”. Bay Harbor, Michigan, July 26, 2009
 38. Speaker, Tenth Annual Update in Internal Medicine Conference. “Update in Infectious Diseases”. Bay Harbor, Michigan, July 25, 2010.
 39. Speaker, Eleventh Annual Update in Internal Medicine Conference. “Update in Infectious Diseases”. Bay Harbor, Michigan, July 31, 2011.
 - 40. Invited Speaker, Infectious Disease Conference, “The Patient at Risk”, Bay Regional Hospital-McLaren Health Care, Bay City, Michigan. March 227, 2012.**
 - 41. Invited Speaker, “Staphylococcal Infections” Mid-Michigan Medical Center, Midland, Michigan, November 1, 2012**
 - 42. Speaker, Thirteenth Annual Update in Internal Medicine Conference. ‘Update in Infectious Diseases’. Bay Harbor, Michigan, July 28, 2013.**

- 43. Invited Speaker, Infectious Disease Grand Rounds, Houston, TX, October 5, 2013.**
- 44. Speaker, 14h Annual Update in Internal Medicine Conference. “Update on MRSA Infections”, Bay Harbor, Michigan, July 25-27, 2014**

INVITED SEMINARS AND GRAND ROUNDS

1. Grand Rounds, Botsford Hospital, Farmington, MI, September 9, 1997.
2. Grand Rounds, Hurley Hospital Medical Center, Flint, MI, February, 1998.
3. Grand Rounds: Antibiotic Resistance, Bixby Hospital, Adrian, MI, October 13, 1999.
4. Grand Rounds, Serious Gram-Positive Infection, Lutheran Hospital Medical Center. Fort Wayne, IN, January 23, 2001.
5. Grand Rounds, Herpes Simplex Virus Encephalitis, William Beaumont Hospital, Royal Oak, MI, January 24, 2001.
6. Grand Rounds, Infective Endocarditis, Henry Ford Hospital, February 14, 2001.
7. Grand Rounds. “Update on Infective Endocarditis”, St. John Hospital, Detroit, Michigan, October 25, 2005.
8. Grand Rounds. “Update in MRSA infections”, Wayne State University. Detroit, Michigan. November 6, 2007.
9. Infectious Disease Grand Rounds, “Update in Staphylococcal Infections and MRSA”, St. Joseph Mercy Hospital, Ann Arbor, Michigan, April 17, 2008.
10. Infectious Disease seminar, “Staphylococcal Infections, update and therapeutic options”, Oklahoma State University, May 9, 2008.
11. Grand Rounds, “The Changing Face of Staphylococcal Infections”, George Washington University Hospital, Washington, D.C., June 17, 2008.
12. Infectious Disease Seminar, “Staphylococcal Infections, update and therapeutic options”, Howard University Division of Infectious Diseases, Washington, D.C., June 17, 2008.
13. Grand Rounds, “The Emerging Threat of Staphylococcal Infections”, St. Mary’s of Michigan Hospital, Saginaw, Michigan, September 4, 2008.
14. Grand Rounds, “What’s New About Endocarditis”, Wayne State University, March 17, 2009.
15. Infectious Disease seminar, “MRSA infections”, Veterans Administration Hospital/University of

New Mexico, Albuquerque, New Mexico, August 24, 2009.

16. Grand Rounds, "MRSA: the Latest Infectious Disease Crisis", Presbyterian Hospital, Albuquerque, New Mexico, August 25, 2009.
17. Grand Rounds, "MRSA: Update and Recommendations" Beaumont Hospital East, Grosse Pointe, Michigan, September 17, 2009.
18. Grand Rounds, "MRSA Infections", Botsford Hospital, Farmington Hills, Michigan, December 8, 2009.
19. Infectious Disease Grand Rounds, "MRSA Bacteremia and Endocarditis", East Carolina University, Greenville, NC, January 6, 2010.
20. Grand Rounds, "What's New In Endocarditis?", Washington Hospital Medical Center, Washington DC, January 13, 2010.
21. Infectious Disease Grand Rounds, "Endocarditis, Update", United States Naval Hospital, San Diego, CA, January 15, 2010.
22. Internal Medicine Grand Rounds, "Update on Staphylococcus Infections", Michigan State University Kalamazoo Center for Medical Studies, Borgess Medical Center, Kalamazoo, MI, March 10, 2010.
23. Internal Medicine Grand Rounds, "What's New About Endocarditis", Wayne State University, Detroit, MI, April 13, 2010.
24. Internal Medicine Grand Rounds, "Infective Endocarditis", University of Arkansas Medical Center, April 15, 2010.
25. Neurology Grand Rounds, "Infective Endocarditis and the Central Nervous System", Veterans Administration Hospital, Detroit, MI June 25, 2010.
26. Infectious Disease Grand Rounds, "Staphylococcal Infections", St. Joseph Mercy Hospital, Ann Arbor, MI, July 28, 2010.
27. Wayne State University MPH Public Health Seminar Series, "MRSA: The Latest Infectious Disease Crises", Wayne State University, October 4, 2010.

